Singapore, Jan. 5 -- Singapore-based Hyphens Pharma International has granted the rights to commercialise its innovative product, Cerapro(R) MED Skin Barrier Cream, to Louis Widmer SA via a licensing, supply and commercialisation agreement that covers six European countries, namely Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.

Atopic dermatitis, a common form of eczema, affects millions across all age groups. Elevated skin pH and impaired skin barrier function are key drivers of this skin condition.

Cerapro(R), with its patented formulation, lowers skin pH and helps restore the skin barrier. Approved as a CE-marked medical device under the stringent European Medical Device Regulation (MDR), Cerapro(R) off...